Inbec要注意什么呢？

The ingredients of Suimeike () are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir.

You should be aware of the following risks when taking Suimeikan:

Regardless of patient race, patients should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B*5701 allele, he should not take products containing abacavir.

Transmitting HIV: Although viral suppression with antiretroviral treatment has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be ruled out. Precautions should be taken to prevent transmission in accordance with national guidance.

Hypersensitivity reactions: Both abacavir and dolutegravir have a risk of triggering a hypersensitivity reaction (HSR) and share some common characteristics, such as fever and/or rash and other symptoms indicating involvement of multiple organs. It is clinically impossible to determine whether abacavir or dolutegravir is responsible for a hypersensitivity reaction that occurs with Trimeq. Hypersensitivity reactions have been observed to occur more commonly with abacavir, some of which can be life-threatening and, in rare cases, fatal if not managed appropriately. Patients who test positive for the HLA-B*5701 allele are at higher risk of developing abacavir hypersensitivity reactions. However, abacavir hypersensitivity reactions are reported less frequently in patients who do not carry this allele.

After discontinuing Trimax () due to a suspected hypersensitivity reaction, you should never restart Trimax or any other medicine containing abacavir or dolutegravir. After a suspected hypersensitivity reaction to abacavir, symptoms may return within hours if abacavir-containing medicines are restarted. Relapses are generally more severe than the initial episode and may include life-threatening hypotension and death. To avoid re-dosing abacavir and dolutegravir, patients with suspected hypersensitivity reactions should be instructed to discard remaining Inbec tablets.